Tolero Pharmaceuticals Announces Presentation At American Association for Cancer Research Describing A Relationship Between Biomarkers And Response To Alvocidib In Patients With Chronic Lymphocytic Leukemia
Published: Apr 07, 2014
Tolero Pharmaceuticals, Inc., a clinical-stage company developing treatments for serious hematological diseases, today announced that a poster related to its development program alvocidib, a potent cyclin-dependent kinase in development for a variety of hematologic disorders, was presented at the 105th Annual Meeting of the American Association for Cancer Research (AACR) in San Diego. The poster, “Bcl-xL Dependence Predicts Response to Alvocidib in Chronic Lymphocytic Leukemia Patients,” was presented on Sunday, April 6, 2014, at 1:00 p.m. in collaboration with Eutropics Pharmaceuticals, The Translational Genomics Research Institute, Ohio State University and the Duke Cancer Institute.
Help employers find you! Check out all the jobs and post your resume.